Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Syphilis

Historically known for its insidious progression and multi-stage presentation, syphilis has been a significant public health concern. At our company, we are committed to advancing syphilis vaccine and therapy development through cutting-edge research and comprehensive services.

Overview of Syphilis

Syphilis is a sexually transmitted infection (STI) caused by the bacterium Treponema pallidum. It is characterized by distinct stages: primary, secondary, latent, and tertiary syphilis. Each stage presents unique features, beginning with painless ulcers at the site of infection and progressing to systemic manifestations if untreated. The prevalence of syphilis has seen a resurgence in recent years, especially among high-risk populations, including men who have sex with men (MSM) and individuals with multiple sexual partners.

Immune response to TPA infection. Fig.1 Immune response to Treponema pallidum subspecie pallidum (TPA) infection. (Ávila-Nieto C., et al., 2023)

Vaccine Development for Syphilis

The development of a syphilis vaccine has been a challenging endeavor due to the complex immunobiology of Treponema pallidum. Unlike other bacterial vaccines, traditional approaches such as inactivated or subunit vaccines have not yielded a successful candidate.

Recent scientific insights have led to a renewed interest in syphilis vaccine development. The focus has shifted towards understanding the immune response to T. pallidum, particularly the identification of protective antigens and the characteristics of a protective immune response. Preclinical studies have explored the use of outer membrane proteins (OMPs) as potential immunogens. The advent of genetic engineering and bioinformatics has facilitated the prediction of B cell epitopes and the structural modeling of OMPs, which are crucial for vaccine design.

Therapeutics Development for Syphilis

Antibiotic Therapy

Historically, penicillin has been the cornerstone of syphilis therapeutics. Benzathine penicillin G (BPG) is the preferred regimen for all stages of syphilis.

Combination Therapy

Recent studies have investigated the efficacy of combination therapies that include BPG, ceftriaxone, and doxycycline.

Alternative Antibiotics

Drugs such as azithromycin and tetracycline derivatives have been evaluated for their potential use in treating syphilis, particularly in penicillin-allergic cases.

Our Services

The development of effective vaccines and therapies for syphilis demands a multidisciplinary approach, integrating cutting-edge scientific research with robust preclinical methodologies. Our services encompass various aspects of vaccine and therapy development:

Vaccine Development

Therapeutic Development

Disease Models

C57BL/6 Mice Models: Treponema pallidum (Nichols strain)
Hamster Models: intradermal infection
Rabbit Models: T. pallidum
Non-human Primate (NHP) Models: rectally transmitted syphilis

Preclinical research is integral to the development pipeline, encompassing immunogenicity studies, efficacy testing, and safety assessments. Comprehensive preclinical studies are conducted to evaluate vaccine candidates and therapeutic approaches before proceeding to human trials. If you are interested in our services, please feel free to contact us.

References

Ávila-Nieto Carlos, et al. "Syphilis vaccine: challenges, controversies and opportunities." Frontiers in immunology 14 (2023): 1126170.
Drago, Francesco, et al. "A new enhanced antibiotic treatment for early and late syphilis." Journal of Global Antimicrobial Resistance 5 (2016): 64-66.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.